{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:23Z","timestamp":1790400383728,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijrobp.2022.05.023","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T18:24:33Z","timestamp":1654799073000},"page":"910-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-1691","authenticated-orcid":false,"given":"Alexander D.","family":"Sherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharakeswara K.","family":"Bathala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikesh","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Ashleigh","family":"Guadagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey W.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol J.","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.05.023_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0002","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0003","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0004","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/jnci\/58.6.1735","article-title":"Growth curve of an experimental solid tumor following radiotherapy","volume":"58","author":"Norton","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0006","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0007","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2021.08.005","article-title":"Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC","volume":"163","author":"Farooqi","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0008","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41416-020-01128-5","article-title":"Metastasis-directed therapy for oligometastasis and beyond","volume":"124","author":"Beckham","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0009","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0012","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2020.02.468","article-title":"Curing metastatic disease with ablative radiation therapy: Separating truth from wish","volume":"107","author":"Kamran","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0014","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijrobp.2020.03.009","article-title":"Curing metastatic disease with radiation therapy: Myth or reality? Arguing for reality","volume":"107","author":"Rahimi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0015","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0017","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0019","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ygyno.2021.12.022","article-title":"Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis","volume":"164","author":"Corrigan","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0020","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-20-3337","article-title":"(Oligo)metastasis as a spectrum of disease","volume":"81","author":"Gutiontov","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0021","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: A systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0031","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2014.10.021","article-title":"Stereotactic body radiation therapy for oligometastases to the lung: A phase 2 study","volume":"91","author":"Nuyttens","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0032","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2018.08.027","article-title":"Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for oligometastatic cancer","volume":"103","author":"Sutera","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0034","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0036","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0024","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2020.11.066","article-title":"Stereotactic ablative radiation therapy to all lesions in patients with oligometastatic cancers: A phase 1 dose-escalation trial","volume":"109","author":"Mercier","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0023","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2020.01.010","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure","volume":"145","author":"Pasalic","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0026","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A Prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0027","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.15541","article-title":"Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation","volume":"129","author":"De","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0028","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: A single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0029","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.21.01719","article-title":"Practical management of oligometastatic non-small-cell lung cancer","volume":"40","author":"Jasper","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.023_bib0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijrobp.2019.10.038","article-title":"Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: Translational correlatives from a mature randomized phase II trial","volume":"106","author":"Tang","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622004758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622004758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:05:02Z","timestamp":1759745102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622004758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0360301622004758"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.023","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}